SCHEDULE: State Street Reports 5.5% Stake in Lexeo Therapeutics

State Street Corporation has disclosed a beneficial ownership of 5.5% in Lexeo Therapeutics Inc. as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating a passive investment stake in Lexeo Therapeutics Inc.
• The filing reports that State Street Corporation beneficially owns 4,354,775 shares of Lexeo Therapeutics Inc. common stock.
• This ownership represents 5.5% of the class of securities.
• The date of the event requiring this filing is June 30, 2026.
• State Street Corporation is identified as a healthcare (HC) type of reporting person.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without new strategic information or significant changes in holdings.

Positives

• State Street Corporation's investment indicates confidence in Lexeo Therapeutics' potential, as it is a significant institutional holder.
• The passive nature of the filing suggests no intent to influence or control the company's management or operations.

Negatives

• The filing does not provide any new strategic insights or operational updates for Lexeo Therapeutics.
• The ownership stake is passive, meaning it does not necessarily translate to active support or strategic partnership.

Risks

• As a passive investment, the stake does not mitigate existing risks faced by Lexeo Therapeutics.
• The filing does not offer any forward-looking statements or risk disclosures specific to Lexeo Therapeutics' business operations.

Future Outlook

No specific future outlook or guidance for Lexeo Therapeutics is provided in this filing, as it is a disclosure of ownership by an institutional investor.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that institutional ownership, as reported in Schedule 13G filings, is a common indicator of investor interest in a company. State Street Corporation is a major custodian and investment manager, and its passive stake suggests Lexeo Therapeutics is on the radar of large financial institutions.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which can be viewed positively for long-term stability, but offers no immediate strategic direction.
• Management: The passive nature of the stake means no immediate pressure or influence on management decisions from State Street Corporation.
• Creditors: No direct impact on creditors is indicated by this ownership disclosure.

Next Steps

• State Street Corporation will continue to hold its shares in Lexeo Therapeutics Inc. in the ordinary course of business.
• Future filings will be made by State Street Corporation if its ownership stake changes significantly.

Key Dates

Keywords

Lexeo Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare, Common Stock